EGF R Overview
Molecule Name
Epidermal growth factor receptor erbB1
Synonyms
EGFR,ERBB,ERBB1,HER1,PIG61,mENA
Drug Development Progress
Drugs in Clinical Trials203
Approved Drugs39
Highest Development StageApproved
Target Synonym
Epidermal Growth Factor Receptor (Avian Erythroblastic Leukemia Viral (V-Erb-B) Oncogene Homolog)，Erythroblastic Leukemia Viral (V-Erb-B) Oncogene Homolog (Avian)，Avian Erythroblastic Leukemia Viral (V-Erb-B) Oncogene Homolog，Epidermal Growth Factor Receptor Tyrosine Kinase Domain，Cell Proliferation-Inducing Protein 61，Cell Growth Inhibiting Protein 40，EC 2.7.10.1，NISBD2，PIG61，MENA，EC:2.7.10.1，EC 2.7.10，Receptor tyrosine-protein kinase erbB-1，Proto-oncogene c-ErbB-1，Epidermal growth factor receptor，EGFR，Erb-B2 Receptor Tyrosine Kinase 1，ERBB1，ERBB，HER1
Background
The epidermal growth factor receptor (EGFR; ErbB-1; HER1 in humans) is the cell-surface receptor for members of the epidermal growth factor family (EGF-family) of extracellular protein ligands. The epidermal growth factor receptor is a member of the ErbB family of receptors, a subfamily of four closely related receptor tyrosine kinases: EGFR (ErbB-1), HER2/c-neu (ErbB-2), Her 3 (ErbB-3) and Her 4 (ErbB-4). Mutations affecting EGFR expression or activity could result in cancer.
EGF R Product List
You Have Viewed 0 Of 0 Results
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| YK-029A | YK-029A; YK-209A; YK-209-A; YK-029-A | Phase 3 Clinical | Hainan Yuekang Biomedicine Co Ltd | Carcinoma, Non-Small-Cell Lung; Drug-Related Side Effects and Adverse Reactions | Details |
| Sutetinib Maleate | Phase 3 Clinical | Jiangsu Maidu Pharmaceutical R & D Co Ltd, Jiangsu Suzhong Pharma Group Co Ltd | Carcinoma, Non-Small-Cell Lung; Solid tumours | Details | |
| Olafertinib | CK-101; RX-518; CS-2481; EGFR-IN-3 | Phase 3 Clinical | Suzhou Neupharma Co Ltd | Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Lung Diseases; Lung Neoplasms | Details |
| Cetuximab biosimilar (AlphaMab) | KN-005 | Phase 3 Clinical | Suzhou Alphamab Co Ltd | Anus Neoplasms; Colorectal Neoplasms; Head and Neck Neoplasms; Urinary Bladder Neoplasms | Details |
| Sacibertinib | Hemay-022 | Phase 3 Clinical | Tianjin Hemay Pharmaceutical Co Ltd, Xiajiang Hemei Pharmaceutical Co Ltd | Breast Neoplasms; Foodborne Diseases | Details |
| HA121-28 | HA121-28; SYHA121-28 | Phase 3 Clinical | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co Ltd | Bile Duct Neoplasms; Biliary Tract Neoplasms; Carcinoma, Non-Small-Cell Lung; Esophageal Neoplasms; Lung Neoplasms; Medullary thyroid cancer (MTC); Neoplasms; Solid tumours | Details |
| Cetuximab biosimilar (R-Pharm) | RPH-002 | Phase 3 Clinical | R-Pharm Jsc | Head and Neck Neoplasms; Pancreatic Neoplasms; Squamous Cell Carcinoma of Head and Neck | Details |
| BEBT-109 | BEBT-109 | Phase 3 Clinical | Guangzhou BeBetter Medicine Technology Co | Carcinoma, Non-Small-Cell Lung | Details |
| Immunomodulatory progenitor cell therapy (Celixir) | Phase 3 Clinical | Celixir | Cardiomyopathies; Endomyocardial Fibrosis | Details | |
| Izalontamab | SI-B001; SI-1X6.4 | Phase 3 Clinical | Sichuan Baili Pharmaceutical Co Ltd | Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Colorectal Neoplasms; Digestive System Neoplasms; Esophageal Squamous Cell Carcinoma; Head and Neck Neoplasms; Neoplasms, Glandular and Epithelial; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms | Details |
| Ruserontinib | SKLB-1028 | Phase 3 Clinical | CSPC Pharmaceutical Group Ltd, Sichuan University | Leukemia, Myeloid; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Solid tumours | Details |
| Pimurutamab | HLX-07 | Phase 3 Clinical | Carcinoma, Adenosquamous; Carcinoma, Basosquamous; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Colorectal Neoplasms; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Lung Neoplasms; Nasopharyngeal Carcinoma; Rectal Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms | Details | |
| Becotatug | JMT-101 | Phase 3 Clinical | Shanghai Jmt-Bio Inc | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Squamous Cell Carcinoma; Nasopharyngeal Carcinoma; Rectal Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck | Details |
| Cetuxima-β | Phase 3 Clinical | Sun Yat-Sen University | Colorectal Neoplasms | Details | |
| HS-20117 | HS-20117; PM1080; PM-1080 | Phase 3 Clinical | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Solid tumours | Details | |
| SYS-6010 | SYS-6010; CPO-301; CPO301; SYS6010 | Phase 3 Clinical | Jushi Biopharmaceutical Co Ltd | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Esophageal Squamous Cell Carcinoma; Lung Neoplasms; Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck | Details |
| IAE-0972 | IAE-0972 | Phase 3 Clinical | SunHo (China) BioPharmaceutical Co Ltd | Carcinoma, Basosquamous; Carcinoma, Hepatocellular; Colorectal Neoplasms; Nasopharyngeal Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck | Details |
| Nimotuzumab biosimilar (IBC Generium) | Phase 3 Clinical | International Biotechnology Center Generium Llc | Head and Neck Neoplasms | Details | |
| Depatuxizumab mafodotin | ABT-414; ABT-414/806 | Phase 3 Clinical | Abbvie Inc | Carcinoma, Squamous Cell; Glioblastoma; Glioma; Gliosarcoma | Details |
| EG-007 | EG-007 | Phase 3 Clinical | Evergreen Therapeutics Inc | Endometrial Neoplasms | Details |
| Larotinib Mesylate | Z-650 | Phase 3 Clinical | Guangdong Dongyangguang Pharmaceutical Co Ltd | Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Pancreatic Neoplasms; Solid tumours | Details |
| Ametumumab | SY-101 | Phase 2 Clinical | Institute of Bioengineering Academy of Military Medical Sciences Chinese People's Liberation Army, Shanghai Serum Bio-Technology Co Ltd | Colorectal Neoplasms; Solid tumours | Details |
| Recombinant anti-human EGFR antibody/IL-10 bispecific Fc fusion protein(Dingfu Biotarget) | CmAb-(IL10)2; DF203; DF-203 | Phase 2 Clinical | Dingfu Biotarget Co Ltd | Ascites; Pleural Effusion, Malignant; Solid tumours | Details |
| Petosemtamab | MCLA-158 | Phase 2 Clinical | Merus Nv | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms | Details |
| GC-1118A | GC-1118; GC-1118A | Phase 2 Clinical | GC Biopharma Corp | Colorectal Neoplasms; Neoplasm Metastasis; Solid tumours; Stomach Neoplasms | Details |
| Durvalumab/Gefitinib | Phase 2 Clinical | Medimmune | Carcinoma, Non-Small-Cell Lung | Details | |
| Pamvatamig | MCLA-129 | Phase 2 Clinical | Merus Nv | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Head and Neck Neoplasms; Solid tumours | Details |
| JNJ-26483327 | JNJ-26483327; MTKi-327; BGB-102 | Phase 2 Clinical | Johnson & Johnson | Macular Degeneration; Neoplasms; Solid tumours | Details |
| HER-1 vaccine (Center of Molecular Immunology) | HER1-ECD; HER1-VSSP; HER-1-ECD-VSSP | Phase 2 Clinical | Center Of Molecular Immunology | Neoplasms | Details |
| WSD-0922 | WSD0922; WSD-0922 | Phase 2 Clinical | Wayshine Biopharm International Ltd | Astrocytoma; Carcinoma, Non-Small-Cell Lung; Glioblastoma | Details |
| C225-ILS-DOX | C225-ILs-dox | Phase 2 Clinical | Universitaetsspitals Basel | Breast Neoplasms | Details |
| Nazartinib | EGF-816; EGFRmut-TKI EGF816 | Phase 2 Clinical | Novartis Pharma Ag | Adenocarcinoma; Bronchial Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Lung Neoplasms; Triple Negative Breast Neoplasms | Details |
| Sapitinib | AZD-8931 | Phase 2 Clinical | Astrazeneca Plc | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Neoplasms; Metastatic breast cancer; Neoplasm Metastasis; Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| Tesevatinib | XL-647; KD-020; KD-019; EXEL-7647 | Phase 2 Clinical | Exelixis Inc | Brain metastases; Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Glioblastoma; Neoplasm Metastasis; Neoplasms; Polycystic Kidney, Autosomal Dominant; Polycystic Kidney, Autosomal Recessive | Details |
| BB-101 (Blue Blood Biotech/National Cheng Kung University) | BB-101 | Phase 2 Clinical | Blue Blood Biotech Corp, National Cheng Kung University | Diabetic Foot | Details |
| Gozanertinib | ABT-101; DBPR-112 | Phase 2 Clinical | National Health Research Institutes | Carcinoma, Non-Small-Cell Lung; Head and Neck Neoplasms; Lung Neoplasms; Solid tumours | Details |
| Panitumumab-IRDye800CW (Stanford University) | Phase 2 Clinical | Stanford University | Brain Neoplasms; Head and Neck Neoplasms; Squamous Cell Carcinoma of Head and Neck | Details | |
| AMX-3009 Maleate | AMX-3009; AMX3009马来酸 | Phase 2 Clinical | Anrun Medicine Technology (Suzhou) Co Ltd | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Pancreatic Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms | Details |
| Allitinib Tosylate | AST-6; ALS-1306; AST-1306 | Phase 2 Clinical | Shanghai Allist Pharmaceutical Technology Co Ltd | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| Demupitamab | SCT-200 | Phase 2 Clinical | SinoCelltech Ltd | Biliary Tract Neoplasms; Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Esophageal Squamous Cell Carcinoma; Gallbladder Neoplasms; Head and Neck Neoplasms; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms | Details |
| Varlitinib Ditosylate | SPS-4370; ASLAN-001; ARRY-334543; ARRY-543; QBT-01 | Phase 2 Clinical | Array Biopharma | Bile Duct Neoplasms; Biliary Tract Neoplasms; Breast Neoplasms; Cholangiocarcinoma; Metastatic breast cancer; Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| Cetuximab-IRDye800CW (University Medical Center Groningen) | Phase 2 Clinical | Umcg The University Medical Center Groningen | Lung Neoplasms; Penile Neoplasms; Rectal Neoplasms | Details | |
| Selatinib Ditosilate | QLNC-120 | Phase 2 Clinical | Qilu Antibiotics (Linyi) Pharmaceutical Co Ltd, Qilu Pharmaceutical Co Ltd | Breast Neoplasms | Details |
| VBC-101-F11 | VBC-101; VBC101F11; VBC101 | Phase 2 Clinical | Shanghai Orange Sail Pharmaceutical Co Ltd | Solid tumours | Details |
| EHT-102 | EHT-102; EHT-0102 | Phase 2 Clinical | Diaxonhit | Autosomal recessive deafness-9; Breast Neoplasms; Colonic Neoplasms; Hearing Loss; Ovarian Neoplasms | Details |
| NRC-2694 | NRC-2694; NRC-2694A; NRC-2694-A | Phase 2 Clinical | Natco Pharma | Carcinoma | Details |
| Bafisontamab | FIT-013a; EMB-01 | Phase 2 Clinical | Shanghai Epimab Biotherapeutics, Inc | Biliary Tract Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Digestive System Neoplasms; Gastrointestinal Neoplasms; Liver Neoplasms; Lung Neoplasms; Neoplasm Metastasis; Neoplasms; Stomach Neoplasms | Details |
| Recombinant anti-EGFR chimeric monoclonal antibody (Shanghai CP Guojian) | CPGJ-602; 602; CPGJ602; CPGJ 602 | Phase 2 Clinical | Sunshine GuoJian Pharmaceutical (Shanghai) Co Ltd | Colorectal Neoplasms | Details |
| JY-016 | JY-016 | Phase 2 Clinical | Beijing Eastern Biotech Co Ltd, Beijing Jingyitaixiang Technology Development Co Ltd | Colorectal Neoplasms; Lung Neoplasms; Solid tumours | Details |
| ABL-104 | ABL-104; YH-32364 | Phase 2 Clinical | Abl Bio Inc | Colorectal Neoplasms; Head and Neck Neoplasms; Solid tumours | Details |
| GB-263 | GB-263; GB-263T | Phase 2 Clinical | Genor Biopharma Co Ltd | Carcinoma, Non-Small-Cell Lung; Neoplasms; Solid tumours | Details |
| Enozertinib | ORIC-114; VRN-07 | Phase 2 Clinical | Voronoi Inc | Carcinoma, Non-Small-Cell Lung; Solid tumours | Details |
| Silevertinib | BDTX-1535 | Phase 2 Clinical | Black Diamond Therapeutics Inc | Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Central Nervous System Diseases; Glioblastoma; Glioma | Details |
| Anti-CD3 × Anti-EGFR Bispecific-armed T Cells (EGFR BATs) therapy | Phase 2 Clinical | University Of Virginia | Glioblastoma; Pancreatic Neoplasms | Details | |
| 89Zr-DFO-Nimotuzumab | Phase 2 Clinical | University Of Saskatchewan | Colorectal Neoplasms; Lung Neoplasms | Details | |
| Kenitinib | Phase 2 Clinical | Suzhou Teligene Ltd | Carcinoma, Non-Small-Cell Lung; Lymphoma, B-Cell | Details | |
| TQB-6411 | TQB-6411; TQB6411 | Phase 2 Clinical | Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | Esophageal Neoplasms; Lung Neoplasms; Neoplasms | Details |
| JS-212 | JS212; JS-212 | Phase 2 Clinical | Shanghai Junshi Biosciences Co Ltd | Colorectal Neoplasms; Esophageal Squamous Cell Carcinoma; Lung Neoplasms; Solid tumours | Details |
| BH-30643 | BH-30643 | Phase 2 Clinical | BlossomHill Therapeutics Inc | Carcinoma, Non-Small-Cell Lung | Details |
| FH-006 | FH-006; FH006 | Phase 2 Clinical | Jiangsu Hengrui Medicine Co Ltd, Shanghai Fuhong Biomedical Co Ltd | Lung Neoplasms; Solid tumours | Details |
| SKB-571 | SKB-571; MK-2750; SKB571 | Phase 2 Clinical | Sichuan Kelun-Biotech Biopharmaceutical Co Ltd | Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Solid tumours | Details |
| DB-1418 | AVZO-1418; DB-1418 | Phase 2 Clinical | Duality Biologics (Suzhou) Co Ltd | Lung Neoplasms; Neoplasms, Glandular and Epithelial; Solid tumours | Details |
| Anti-CD3 x Anti-EGFR Bispecific Antibody (EGFRBi) Armed Fresh Peripheral Blood Mononuclear Cells therapy(University Of Virginia) | Phase 2 Clinical | University Of Virginia | Pancreatic Neoplasms | Details | |
| WSD-0922-FU | WSD0922-FU; WSD-0922-FU | Phase 2 Clinical | Wayshine Biopharm International Ltd | Astrocytoma; Carcinoma, Non-Small-Cell Lung; Glioblastoma; Lung Neoplasms; Neoplasms; Solid tumours | Details |
| KY-0301 | RB-601; KY-0301 | Phase 2 Clinical | Novatim Immune Therapeutics (Zhejiang) Co Ltd | Solid tumours | Details |
| Neratinib (Fukang (Shanghai) Health Technology) | CVL009; CVL-009 | Phase 2 Clinical | Convalife (Shanghai) Co Ltd | Carcinoma, Non-Small-Cell Lung; Solid tumours; Uterine Neoplasms | Details |
| PRO-1286 | PRO-1286; GEN1286; GEN-1286 | Phase 2 Clinical | ProfoundBio (Suzhou) Co Ltd | Neoplasms; Solid tumours | Details |
| TQB-2922 | TQB2922; TQB-2922 | Phase 2 Clinical | Nanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group | Colorectal Neoplasms; Neoplasms | Details |
| TRX-221 | TRX-221 | Phase 2 Clinical | Therapex Corp | Carcinoma, Non-Small-Cell Lung | Details |
| E-EDV-D682 | PNU-15982; E-EDV-D682; EGFR-EDV-PNU-15982 | Phase 2 Clinical | Engeneic Ltd | Carcinoma, Pancreatic Ductal; Pancreatic Neoplasms | Details |
| IBI334 | IBI334; IBI-334 | Phase 2 Clinical | Solid tumours | Details | |
| SHR-9839 | SHR-9839; SHR9839 | Phase 2 Clinical | Shanghai Hengrui Pharmaceutical Co Ltd | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Neoplasm Metastasis; Solid tumours | Details |
| DF9001 | DF-9001 | Phase 2 Clinical | Dragonfly Therapeutics Llc | Solid tumours | Details |
| DWP-708 | DWP-708 | Phase 2 Clinical | Daewoong Pharmaceutical Co Ltd | Acneiform Eruptions | Details |
| BBT-207 | BBT-207 | Phase 2 Clinical | Bridge Biotherapeutics Inc | Carcinoma, Non-Small-Cell Lung | Details |
| H-002 | H-002 | Phase 2 Clinical | Nanjing Hongyun Biological Technology Co Ltd | Carcinoma, Non-Small-Cell Lung; Neoplasms | Details |
| DAJH-1050766 | DAJH1050766; DA-0157; DAJH-1050766 | Phase 2 Clinical | Chengdu Diao Jiuhong Pharmaceutical Factory | Carcinoma, Non-Small-Cell Lung | Details |
| Anti-CTLA-4/PD-1 expressing EGFR-CAR-T | Phase 2 Clinical | Shanghai Cell Therapy Research Institute | Solid tumours | Details | |
| Anti-EGFR CAR-T cell therapy (Beijing Pregene) | Phase 2 Clinical | Shenzhen Pregene Biopharma Co Ltd | Colorectal Neoplasms | Details | |
| HS-10375 | HS-10375 | Phase 2 Clinical | Jiangsu Hansoh Pharmaceutical Group Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
| SMET-12 | SMET-12 | Phase 2 Clinical | Zhejiang Shimai Pharmaceutical Co Ltd | Carcinoma, Non-Small-Cell Lung; Solid tumours | Details |
| EO-1001 | NT-113; APL-122 | Phase 2 Clinical | Edison Pharmaceuticals Inc | Neoplasms | Details |
| AP-L1898 | AP-L1898; JS111; WJ-002 | Phase 2 Clinical | Wigen Biomedicine technology (Shanghai) Co Ltd | Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Solid tumours | Details |
| BPI-361175 | BPI-361175 | Phase 2 Clinical | Betta Pharmaceuticals Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
| CKD-702 | CKD-702 | Phase 2 Clinical | Chong Kun Dang Pharmaceutical Corp | Carcinoma, Non-Small-Cell Lung; Stomach Neoplasms | Details |
| Marlotamig | REGN-7075 | Phase 2 Clinical | Regeneron Pharmaceuticals Inc | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Solid tumours | Details |
| JRF-103 | JRF103; JRF-103 | Phase 2 Clinical | Shenzhen Jinrui Foundation Biotechnology Co Ltd | Solid tumours | Details |
| Anti-EGFR-IL-dox (Swiss Group for Clinical Cancer Research) | Phase 2 Clinical | Schweizerische Arbeitsgemeinschaft Für Klinische Krebsforschung | Breast Neoplasms | Details | |
| Epertinib | S-222611; RT1978; RT-1978 | Phase 2 Clinical | Shionogi & Co Ltd | Neoplasms | Details |
| Pirotinib Hydrochloride | KBP-5209 | Phase 2 Clinical | Shandong Xuanzhu Pharmaceutical Technology Co Ltd | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Solid tumours | Details |
| Humanized anti-EGFR monoclonal antibody (Hualan Biological Engineering/Henan shengming biotechnology) | Phase 2 Clinical | Henan Shengming Biotechnology Research Institute Co Ltd, Hualan Ankang Biotechnology Co Ltd | Colorectal Neoplasms | Details | |
| Anti-CD3/anti-EGFR -activated T cells (Barbara Ann Karmanos Cancer Institute) | Phase 2 Clinical | Barbara Ann Karmanos Cancer Institute, University Of Virginia | Pancreatic Neoplasms | Details | |
| Ascorbic Acid/Menadione | Phase 2 Clinical | Ic-Medtech Co, Summa Health System | Joint Diseases; Prostatic Neoplasms | Details | |
| Cetuximab biosimilar (Guilin Sanjin) | CDP-1; BC-001 | Phase 1 Clinical | Dragonboat Biopharmaceutical, Guilin Sanjin Pharmaceutical Co Ltd | Colorectal Neoplasms; Neoplasms; Solid tumours | Details |
| TQB3804 | TQB-3804 | Phase 1 Clinical | Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | Carcinoma, Non-Small-Cell Lung; Neoplasms | Details |
| D2C7-IT | D2C7-(scdsFv)-PE38 KDEL; scds-D2C7 -PE38KDEL; D2C7-Immunotoxin; D2C7-IT | Phase 1 Clinical | Duke University, Istari Oncology Inc | Glioblastoma; Glioma | Details |
| SC-CAR4BRAIN | Phase 1 Clinical | Seattle Children'S Hospital | Carcinoma; Carcinoma, Hepatocellular; Central Nervous System Neoplasms; Desmoplastic Small Round Cell Tumor; Diffuse Intrinsic Pontine Glioma; Diffuse midline glioma; Endodermal Sinus Tumor; Hepatoblastoma; Liposarcoma; Neoplasms, Germ Cell and Embryonal; Neuroblastoma; Neurofibrosarcoma; Osteosarcoma; Retinoblastoma; Rhabdoid Tumor; Rhabdomyosarcoma; Sarcoma; Sarcoma, Clear Cell; Sarcoma, Ewing; Sarcoma, Synovial; Solid tumours; Wilms Tumor | Details | |
| BPI-15086 | BPI-15086; BPI-15000 | Phase 1 Clinical | Betta Pharmaceuticals Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
| MP-0274 | DARPin-41; SPA-28; CME-114; CME-115; CME-118; CME-119; MP-0274 | Phase 1 Clinical | Molecular Partners Ag | Neoplasms | Details |
| SYN-004 (Synermore Biologics) | LR-004; SYN-004 | Phase 1 Clinical | Lonn Ryonn Pharma Ltd, Synermore Biologics (Suzhou) Co Ltd | Carcinoma; Colorectal Neoplasms; Lymphoma, Large B-Cell, Diffuse; Solid tumours | Details |
| KY-1701 | KY-1701 | Phase 1 Clinical | Jiangsu Kanion Pharmaceutical Co Ltd | Breast Neoplasms | Details |
| Simotinib Hydrochloride | AL-6802; SIM-6802 | Phase 1 Clinical | Advenchen Laboratories Llc, Jiangsu Simcere Pharmaceutical Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
| Double-deleted Vaccinia Virus Plus CD/ SMR | JX-929; vvDD-CDSR | Phase 1 Clinical | Sillajen Inc | Breast Neoplasms; Colorectal Neoplasms; Liver Neoplasms; Melanoma; Pancreatic Neoplasms; Squamous Cell Carcinoma of Head and Neck | Details |
| TQ-B3395 | TQ-B-3395; TQ-B3395; CT-1495 | Phase 1 Clinical | Beijing Centaurus Biopharma Co Ltd, Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasms | Details |
| Antibody-drug nanocell conjugates (EnGeneIC) | EGFR-EDV-RRM1; EGFR-EDV-PLK; EGFR-EDV-Dox | Phase 1 Clinical | Engeneic Ltd | Glioblastoma | Details |
| Cetuximab biosimilar (Shanghai Henlius Biotech) | HLX-05; JZB-29; JZB-28 | Phase 1 Clinical | Colorectal Neoplasms; Squamous Cell Carcinoma of Head and Neck | Details | |
| Recombinant chimeric anti-EGFR monoclonal antibody (Zhejiang Xinwei Shengke Biotechnology) | Phase 1 Clinical | Zhejiang Xinweishengke Biotechnology Co Ltd | Esophageal Neoplasms; Gastroesophageal Junction Neoplasms | Details | |
| Anti-EGFR-bispecific antibody armed activated T-cell therapy (Memorial Sloan Kettering Cancer Center) | Phase 1 Clinical | Memorial Sloan Kettering Cancer Center | Pancreatic Neoplasms | Details | |
| [89Zr]Panitumumab | Phase 1 Clinical | Stanford University, University Of Alabama At Birmingham, Vanderbilt-Ingram Cancer Center | Colonic Neoplasms; Pancreatic Neoplasms; Squamous Cell Carcinoma of Head and Neck | Details | |
| Futuximab/Modotuximab | Sym-004; S95026; S-95026; 992-and-1024 | Phase 1 Clinical | Symphogen A/S | Carcinoma; Colorectal Neoplasms; Glioma; Solid tumours; Squamous Cell Carcinoma of Head and Neck | Details |
| Recombinant chimeric anti-EGFR monoclonal antibody (Qilu Pharmaceutical) | QL-1105 | Phase 1 Clinical | Qilu Pharmaceutical Co Ltd | Solid tumours | Details |
| EGFRvIII-CAR | Phase 1 Clinical | Duke University Medical Center | Glioblastoma | Details | |
| Puvitinib | Phase 1 Clinical | Suzhou Teligene Ltd | Solid tumours | Details | |
| Betatinib | TL-512 | Phase 1 Clinical | Aspedia Llc, Suzhou Teligene Ltd | Carcinoma, Non-Small-Cell Lung | Details |
| KSP-QRH-E3-IRDye800 | Phase 1 Clinical | University Of Michigan | Cholangiocarcinoma | Details | |
| Hemay-020 | Hemay-020 | Phase 1 Clinical | Hainan General Sanyang Pharmaceutical Co Ltd, Tianjin Hemay Pharmaceutical Co Ltd | Carcinoma, Non-Small-Cell Lung; Solid tumours | Details |
| Erlotinib gel (Sol-Gel Technologies) | SGT-210 | Phase 1 Clinical | Sol Gel Technologies Pte Ltd | Keratosis | Details |
| ZN-e4 | ZN-e4; KP-673 | Phase 1 Clinical | Zeno Pharma, Zentalis Pharmaceuticals LLC | Carcinoma, Non-Small-Cell Lung | Details |
| LY-01010 | LY-01010 | Phase 1 Clinical | Luye Pharma Group Ltd | Breast Neoplasms | Details |
| PB-357 | PB-357 | Phase 1 Clinical | Pfizer Inc | Neoplasms | Details |
| ZSP-0391 | ZSP-0391 | Phase 1 Clinical | Guangdong Zhongsheng Pharmaceutical Co Ltd, Wuxi Apptec Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
| Neptinib Di-P-methylbenzenesulfonate | Phase 1 Clinical | Shenzhen Neptunus Pharmaceutical Research Institute Co Ltd | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Stomach Neoplasms | Details | |
| Serclutamab talirine | ABBV-321 | Phase 1 Clinical | Abbvie Inc | Solid tumours | Details |
| Recombinant anti-EGFR chimeric antibody (Harbin Pharmaceutical) | Phase 1 Clinical | Harbin Pharmaceutical Group Holding Co Ltd | Colorectal Neoplasms | Details | |
| E-Sync T Cell Therapy (University of California/National Cancer Institute/California Institute for Regenerative Medicine) | Phase 1 Clinical | University Of California San Francisco | Glioblastoma | Details | |
| 64Cu-NCAB-001 | Phase 1 Clinical | Japan Agency For Medical Research And Development | Pancreatic Neoplasms | Details | |
| anti-EGFR CAR T-cell therapy (Seattle Children's Hospital) | EGFR-806 | Phase 1 Clinical | Seattle Children'S Hospital | Central Nervous System Neoplasms; Solid tumours | Details |
| recombinant EGF/CRM-197 vaccine (Shanghai Humantech Biotechnology) | Phase 1 Clinical | Shanghai Humantech Biotechnology Co Ltd | Carcinoma, Non-Small-Cell Lung; Neoplasms; Solid tumours | Details | |
| anti-EGFRvIII CAR T-cell therapy (Beijing Marino) | Phase 1 Clinical | Beijing Marino Biotechnology Co Ltd | Glioblastoma | Details | |
| naputinib tosilate (Shenzhen Neptunus Bioengineering) | NEP-015 | Phase 1 Clinical | Shenzhen Neptunus Bioengineering Co Ltd | Carcinoma, Non-Small-Cell Lung; Solid tumours | Details |
| CXCR5 modified EGFR chimeric antigen receptor autologous T cells therapy | Phase 1 Clinical | Guangzhou Bio-Gene Technology Co Ltd | Carcinoma, Non-Small-Cell Lung | Details | |
| VRN-11 | VRN11; VRN-110755 | Phase 1 Clinical | Voronoi Inc | Carcinoma, Non-Small-Cell Lung | Details |
| Diakine-DK2 10 (EGFR) | DK210; DK-2-10 | Phase 1 Clinical | Deka Biosciences Inc | Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Genital Neoplasms, Female; Head and Neck Neoplasms; Kidney Neoplasms; Neoplasms; Pancreatic Neoplasms; Skin Neoplasms; Solid tumours | Details |
| HLX-42 | HLX-42; HLX42 | Phase 1 Clinical | Hanlin Biotechnology Co Ltd | Neoplasms; Solid tumours | Details |
| CMAB-017 | CMAB-017 | Phase 1 Clinical | Taizhou Mabtech Pharmaceutical Co Ltd | Colorectal Neoplasms; Esophageal Squamous Cell Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck | Details |
| PF-08046052 | LAVA-1223; SGN-EGFRd2 | Phase 1 Clinical | Lava Therapeutics NV, Seagen Inc, Vu University Medical Center | Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck | Details |
| CM-93 | CM-93 | Phase 1 Clinical | Shanghai Crimson Pharmaceutical Co Ltd | Glioblastoma | Details |
| BLU-701 | BLU-701; BLU 701 | Phase 1 Clinical | Blueprint Medicines Corp | Adenocarcinoma; Bronchial Neoplasms; Carcinoma; Carcinoma, Bronchogenic; Carcinoma, Non-Small-Cell Lung; Lung Diseases; Lung Neoplasms; Neoplasms; Neoplasms, Nerve Tissue; Respiratory Tract Diseases; Respiratory Tract Neoplasms; Thoracic Neoplasms | Details |
| NEOK-002 | ABL209; ABL-209; NEOK002; NEOK-002 | Phase 1 Clinical | Abl Bio Inc, Biocytogen Pharmaceuticals (Beijing) Co Ltd | Neoplasms; Solid tumours | Details |
| QLS-5316 | QLS5316; QLS-5316 | Phase 1 Clinical | Qilu Pharmaceutical Co Ltd | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Gastroesophageal Junction Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms | Details |
| HDM-2024 | HDM2024; HDM-2024 | Phase 1 Clinical | Hangzhou Zhongmei Huadong Pharmaceutical Co Ltd | Solid tumours | Details |
| 188Re-nimotuzumab | Phase 1 Clinical | Cuban Center For Molecular Immunology | Glioma | Details | |
| SIM-0610 | SIM-0610; SIM0610 | Phase 1 Clinical | Simcere Pharmaceutical Group Ltd | Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Neoplasm Metastasis; Solid tumours; Squamous Cell Carcinoma of Head and Neck | Details |
| HJ-004-02 | HJ-004-02; HJ00402 | Phase 1 Clinical | Jing Medicine Technology (Shanghai) Ltd | Carcinoma, Non-Small-Cell Lung | Details |
| TJ-101 (Phrontline Biopharma) | TJ-101 | Phase 1 Clinical | Phrontline Biopharma Co Ltd | Carcinoma, Non-Small-Cell Lung; Esophageal Neoplasms; Prostatic Neoplasms; Solid tumours | Details |
| HLX-48 | HLX-48 | Phase 1 Clinical | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Solid tumours | Details | |
| EPI-326 | EPI-326 | Phase 1 Clinical | EpiBiologics | Carcinoma, Non-Small-Cell Lung; Head and Neck Neoplasms; Squamous Cell Carcinoma of Head and Neck | Details |
| Cetuximab biosimilar (Humanwell Healthcare) | Phase 1 Clinical | Humanwell Healthcare (Group) Co Ltd | Colorectal Neoplasms | Details | |
| HS-20122 | HS-20122; HS20122 | Phase 1 Clinical | Shanghai Hansoh Biomedical Co Ltd | Carcinoma, Non-Small-Cell Lung; Solid tumours | Details |
| ALK-202 | ALK-202; ALK202 | Phase 1 Clinical | Shanghai Allink Biotherapeutics Co Ltd | Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Solid tumours | Details |
| GenSci-139 | GenSci-139; GenSci139 | Phase 1 Clinical | Changchun GeneScience Pharmaceuticals Co Ltd | Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Colorectal Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| Panitumumab biosimilar(Generium) | GNR-107 | Phase 1 Clinical | Generium Pharmaceuticals | Colorectal Neoplasms | Details |
| Sirotinib Maleate | XZP-5491 | Phase 1 Clinical | Shandong Xuanzhu Pharmaceutical Technology Co Ltd | Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Stomach Neoplasms | Details |
| BG-60366 | BG-60366 | Phase 1 Clinical | BeOne Medicines Ltd | Carcinoma, Non-Small-Cell Lung; Lung Neoplasms | Details |
| TQB-3002 | TQB3002; TQB-3002 | Phase 1 Clinical | Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | Carcinoma, Non-Small-Cell Lung; Neoplasms | Details |
| PM1300 | PM-1300; PM1300 | Phase 1 Clinical | Neoplasms | Details | |
| SAR-446368 | SAR446368; SAR-446368; VIR-5525; AMX-525 | Phase 1 Clinical | Amunix Pharmaceuticals Inc | Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck | Details |
| DWP709 | DWP709; DWP-818-1 | Phase 1 Clinical | Daewoong Pharmaceutical Co Ltd | Epidermolysis Bullosa | Details |
| CMDE-005 | CMDE005; CMDE-005; CMD-E005 | Phase 1 Clinical | Zhejiang Shimai Pharmaceutical Co Ltd | Solid tumours | Details |
| BG-T187 | BG-T187; BGT187 | Phase 1 Clinical | BeOne Medicines Ltd | Gastrointestinal Neoplasms; Lung Neoplasms; Solid tumours | Details |
| IBI-3001 | IBI-3001; IBI3001 | Phase 1 Clinical | Solid tumours | Details | |
| BL-B16D1 | BLB16D1; BL-B16D1 | Phase 1 Clinical | Baili-Bio (Chengdu) Pharmaceutical Co Ltd, Sichuan Baili Pharmaceutical Co Ltd | Breast Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck | Details |
| HJ-002-03 | HJ-002-03; HJ00203 | Phase 1 Clinical | Jing Medicine Technology (Shanghai) Ltd | Carcinoma, Non-Small-Cell Lung | Details |
| YL-221 | YL221; YL-221 | Phase 1 Clinical | MediLink Therapeutics Co Ltd | Solid tumours | Details |
| HS-10504 | HS10504; HS-10504 | Phase 1 Clinical | Jiangsu Hansoh Pharmaceutical Group Co Ltd, Shanghai Hansoh Biomedical Co Ltd | Carcinoma, Non-Small-Cell Lung; Lung Neoplasms | Details |
| BPI-520105 | BPI-520105; BPI520105 | Phase 1 Clinical | Betta Pharmaceuticals Co Ltd | Solid tumours | Details |
| SM-2275 | SM-2275; SM2275 | Phase 1 Clinical | Zhuhai StarMab BioMed Technology Ltd | Solid tumours | Details |
| FPI-2107 | [111In]-FPI-2107 | Phase 1 Clinical | Fusion Pharmaceuticals Inc | Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Colorectal Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms | Details |
| FPI-2053 | FPI-2053 | Phase 1 Clinical | Astrazeneca Plc, Fusion Pharmaceuticals Inc | Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Colorectal Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms | Details |
| KK-2260 | KK2260; KK-2260 | Phase 1 Clinical | Kyowa Kirin Co Ltd | Esophageal Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck | Details |
| DM-005 | DM005; YH013; DM-005 | Phase 1 Clinical | Carcinoma, Non-Small-Cell Lung; Solid tumours; Squamous Cell Carcinoma of Head and Neck | Details | |
| FPI-2068 | FPI-2068; [225Ac]-FPI-2068; AZD-2068 | Phase 1 Clinical | Astrazeneca Plc, Fusion Pharmaceuticals Inc | Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Colorectal Neoplasms; Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms | Details |
| KY-1702 | KY-1702; KY1702 | Phase 1 Clinical | Jiangsu Kanion Pharmaceutical Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
| SNC-109 | SNC109; SNC-109 | Phase 1 Clinical | Shanghai Simnova Biotechnology Co Ltd | Glioblastoma | Details |
| HSK-40118 | HSK40118; HSK-40118 | Phase 1 Clinical | Haisco Pharmaceutical Group Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
| Tilatamig samrotecan | AZD9592; AZD-9592 | Phase 1 Clinical | Astrazeneca Plc | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Head and Neck Neoplasms; Solid tumours | Details |
| JANX-008 | EGFR-TRACTr; JANX008; JANX-008 | Phase 1 Clinical | Janux Therapeutics Inc | Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Colorectal Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms | Details |
| TAVO-412 | TAVO-412 | Phase 1 Clinical | Tavotek Biotherapeutics (Hong Kong) Ltd, Tuochuang Biotechnology (Jiangsu) Co Ltd | Neoplasms; Solid tumours | Details |
| NX-019 | NX-019 | Phase 1 Clinical | Nalo Therapeutics Inc | Neoplasms | Details |
| BCG-011 | DM-001; BCG-011 | Phase 1 Clinical | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasms; Solid tumours; Triple Negative Breast Neoplasms | Details | |
| QLH-11811 | QLH-11811; QLH11811 | Phase 1 Clinical | Qilu Pharmaceutical Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
| Losatuxizumab vedotin | ABBV-221; ABBV221 | Phase 1 Clinical | Abbvie Inc | Neoplasms | Details |
| EGFR/B7H3 CAR-T | EGFR/B7H3 CAR-T | Phase 1 Clinical | Second Affiliated Hospital Of Guangzhou Medical University | Lung Neoplasms; Triple Negative Breast Neoplasms | Details |
| DXC004A | DXC-004-A; DXC004A | Phase 1 Clinical | Hangzhou Dac Biotech Company Ltd | Head and Neck Neoplasms; Lung Neoplasms; Solid tumours | Details |
| BB-1705 | BB-1705 | Phase 1 Clinical | Bliss Biopharmaceutical (Hangzhou) Co Ltd | Neoplasm Metastasis; Neoplasms; Solid tumours | Details |
| CART-EGFR-IL13Ra2 | CART-EGFR-IL13Ra2; CAR-T-EGFR-IL-13-Ra-2 | Phase 1 Clinical | University Of Pennsylvania | Glioblastoma | Details |
| EGFR IL12 CART | Phase 1 Clinical | Shenzhen Pregene Biopharma Co Ltd | Colorectal Neoplasms | Details | |
| ERAS-801 | ERAS-801; JGK-068S | Phase 1 Clinical | Regents Of The University Of California | Astrocytoma; Glioblastoma | Details |
| NIP-142 | NIP-142 | Phase 1 Clinical | National Institutes Of Pharmaceutical Research And Development Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
| [111In] Panitumumab | Phase 1 Clinical | Stanford University | Head and Neck Neoplasms; Squamous Cell Carcinoma of Head and Neck | Details | |
| BC-3448 | BC-3448; BC3448 | Phase 1 Clinical | Wuxi BioCity | Solid tumours | Details |
| BGC-0902 | BGC-0902; BG-C0902; BGC0902 | Phase 1 Clinical | Brightgene Bio-Medical Technology Co Ltd | Neoplasms; Solid tumours | Details |
| ABBV-637 | ABBV-637 | Phase 1 Clinical | Abbvie Inc | Carcinoma, Non-Small-Cell Lung; Solid tumours | Details |
| M-1231 | M-1231 | Phase 1 Clinical | Emd Serono Research & Development Institute Inc, Merck Serono | Carcinoma, Non-Small-Cell Lung; Esophageal Neoplasms; Solid tumours | Details |
| HLX-35 | HLX-35; BNA035 | Phase 1 Clinical | Carcinoma, Non-Small-Cell Lung; Solid tumours | Details | |
| WTS-004 | WTS-004 | Phase 1 Clinical | Hangzhou Wutong Tree Pharmaceutical Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
| FCN-411 | FCN-411 | Phase 1 Clinical | Carcinoma, Non-Small-Cell Lung; Lung Neoplasms | Details | |
| ES-072 | ES-072 | Phase 1 Clinical | Zhejiang Bosheng Pharmaceutical Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
| ZZ-06 | ZZ-06 | Phase 1 Clinical | Changchun Intellicrown Pharmaceutical Co Ltd | Solid tumours | Details |
| ABY-029 | ABY-029 | Phase 1 Clinical | Affibody Ab, Dartmouth College, Li-Cor Bioscience | Brain Neoplasms; Glioma; Head and Neck Neoplasms; Sarcoma; Squamous Cell Carcinoma of Head and Neck | Details |
| Lifirafenib | BeiGene-283; BGB-283 | Phase 1 Clinical | BeOne Medicines Ltd | Solid tumours | Details |
| Cetuximab biosimilar (Enzene Biosciences) | Clinical | Enzene Biosciences Ltd | Carcinoma, Squamous Cell | Details | |
| 68Ga-NODAGA-Ac-Cys-ZEGFR:1907 | Clinical | Harbin Medical University | Lung Neoplasms | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Osimertinib Mesylate | AZD-9291; RDL94R2A16; AZD-9291 Mesylate; AZD9291 | Approved | Astrazeneca Plc | 泰瑞沙, Tagrisso | United States | Carcinoma, Non-Small-Cell Lung | Astrazeneca Pharmaceutical Co Ltd | 2015-11-13 | Adenocarcinoma; Adenocarcinoma of Lung; Brain metastases; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Colonic Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Neoplasms; Glioblastoma; Glioma; Head and Neck Neoplasms; Hematologic Neoplasms; Liver Neoplasms; Lung Neoplasms; Lymphoma; Melanoma; Meningeal Neoplasms; Multiple Myeloma; Neoplasm, Residual; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Rectal Neoplasms; Skin Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Thyroid Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Uterine Neoplasms | Details |
| Menadione | Approved | Eli Lilly And Company | Kyrbax | United States | null | Exanthema; Hypoprothrombinemias; Vitamin K Deficiency Bleeding | Details | |||
| PX-070101 | PX-070101 | Approved | Praxis Pharmaceuticals | Colombia | Diabetic Foot | Praxis Pharmaceuticals | 2015-07-01 | Diabetic Foot | Details | |
| Cetuximab biosimilar (Shanghai Zhangjiang Biotechnology) | STI-001; CMAB-009 | Approved | Shanghai Zhangjiang Biotechnology Co Ltd | Enlituo, 恩立妥 | Mainland China | Colorectal Neoplasms | Taizhou Mabtech Pharmaceutical Co Ltd | 2024-06-18 | Colorectal Neoplasms; Neoplasms | Details |
| Cetuximab sarotalocan | RM-1929; ASP-1929 | Approved | Rakuten Medical Inc | Akalux | Japan | Head and Neck Neoplasms | Rakuten Medical Inc | 2020-09-25 | Head and Neck Neoplasms; Squamous Cell Carcinoma of Head and Neck | Details |
| Cetuximab | IMC-C255; BMS-564717; EMD-271786; C-255; GT-MAB-5.2; ch-225; LY-2939777; NSC-714692 | Approved | Bristol-Myers Squibb Company, Eli Lilly And Company, Merck Serono | 爱必妥, Erbitux | United States | Colorectal Neoplasms | Imclone Gmbh | 2004-02-12 | Adenocarcinoma, Mucinous; Carcinoma, Adenoid Cystic; Carcinoma, Basal Cell; Carcinoma, Hepatocellular; Carcinoma, Mucoepidermoid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Carcinoma, Verrucous; Chordoma; Colonic Neoplasms; Colorectal Neoplasms; Complex Regional Pain Syndromes; Endometrial Neoplasms; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esthesioneuroblastoma, Olfactory; Fallopian Tube Neoplasms; Gastrointestinal Neoplasms; Glioblastoma; Glioma; Granuloma, Lethal Midline; Head and Neck Neoplasms; Hypopharyngeal Neoplasms; Laryngeal Neoplasms; Lip Neoplasms; Liver Neoplasms; Lung Neoplasms; Mouth Neoplasms; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Neoplasms; Neoplasms, Squamous Cell; Neoplastic Cells, Circulating; Neuralgia; Nose Neoplasms; Oropharyngeal Neoplasms; Oropharyngeal Squamous Cell Carcinoma (OPSCC); Ovarian Neoplasms; Pancreatic Neoplasms; Papilloma, Inverted; Paranasal Sinus Neoplasms; Peritoneal Neoplasms; Precancerous Conditions; | Details |
| Afatinib Dimaleate | BIBW-2992-MA2; BIBW-2992 | Approved | C.H. Boehringer Sohn Ag & Co. Kg | Gilotrif, Giotrif, Tovok, 吉泰瑞, Tomtovok | United States | Carcinoma, Non-Small-Cell Lung | C.H. Boehringer Sohn Ag & Co. Kg | 2013-07-12 | Adenocarcinoma; Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chordoma; Colorectal Neoplasms; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Gallbladder Neoplasms; Gastroesophageal Junction Neoplasms; Glioblastoma; Glioma; Head and Neck Neoplasms; Hematologic Neoplasms; Liver Diseases; Lung Neoplasms; Lymphoma; Multiple Myeloma; Neoplasm Metastasis; Neoplasms; Neoplasms, Squamous Cell; Neuroectodermal Tumors; Penile Squamous Cell Carcinoma; Prostatic Neoplasms; Renal Insufficiency; Rhabdomyosarcoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Ureteral Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Urologic Neoplasms; Uterine Neoplasms | Details |
| Mifanertinib Maleate | MET-306 | Approved | Suzhou Maitai Bio-Technology Co Ltd | 迈瑞东 | Mainland China | Carcinoma, Non-Small-Cell Lung | Hangzhou Zhongmei Huadong Pharmaceutical Co Ltd | 2025-10-21 | Carcinoma, Non-Small-Cell Lung; Solid tumours | Details |
| Epidermal growth factor biosimilar (RAS Lifesciences) | Approved | Ras Lifesciences | India | Ras Lifesciences | 2012-10-01 | Details | ||||
| Recombinant epidermal growth factor gel (Pavay Gene Pharmaceutical) | Approved | Guilin Huanuowei Gene Pharmaceutical Co Ltd | 易孚 | Mainland China | Skin Ulcer; Burns | Guilin Huanuowei Gene Pharmaceutical Co Ltd | 2002-12-23 | Burns; Skin Ulcer | Details | |
| Becotatug vedotin | MRG-003; MRG003 | Approved | Shanghai Miracogen Inc | 美佑恒 | Mainland China | Nasopharyngeal Carcinoma | Lepu Biopharma Co Ltd | 2025-10-28 | Bile Duct Neoplasms; Biliary Tract Neoplasms; Carcinoma, Basosquamous; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Head and Neck Neoplasms; Nasopharyngeal Carcinoma; Penile Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Thyroid Neoplasms | Details |
| Nimotuzumab | TheraCIMh-R3; YMB-1000; OSAG-10; KI-0502; KI-0501; DE-766; h-R3; OSAG-101; OSAG101 | Approved | Center Of Molecular Immunology, Cimym Biosciences | BIOMAb-EGFR, TheraCIM, 泰欣生, CIMAher, Theraloc, Taixinsheng | India | Head and Neck Neoplasms; Nasopharyngeal Neoplasms | null | 2006-07-21 | Anus Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Colorectal Neoplasms; Esophageal Diseases; Esophageal Squamous Cell Carcinoma; Gastroesophageal Junction Neoplasms; Glioma; Head and Neck Neoplasms; Nasopharyngeal Carcinoma; Nasopharyngeal Diseases; Nasopharyngeal Neoplasms; Neoplasms; Pancreatic Neoplasms; Pancreatic neuroendocrine tumors (pNET); Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms | Details |
| Recombinant epidermal growth factor (Center for Genetic Engineering and Biotechnology/Praxis Pharmaceuticals) | Approved | Center For Genetic Engineering And Biotechnology, Praxis Pharmaceuticals | Heberprot-P | Cuba | Diabetic Foot | null | 2007-09-01 | Diabetic Foot | Details | |
| Erlotinib Hydrochloride | CP-358774-01; RO-0508231; NSC-718781; CP-358774; RG-1415; OSI-774; R-1415 | Approved | Genentech Inc | Tarceva, 特罗凯 | EU | Pancreatic Neoplasms; Carcinoma, Non-Small-Cell Lung | Cheplapharm Registration GmbH | 2004-11-18 | Adenocarcinoma; Adenocarcinoma of Lung; Adenocarcinoma, Bronchiolo-Alveolar; Adenocarcinoma, Mucinous; Adenomatous Polyposis Coli; Adenomatous Polyps; Anus Neoplasms; Astrocytoma; Bile Duct Neoplasms; Brain metastases; Brain Neoplasms; Breast Neoplasms; Breast Neoplasms, Male; Brenner Tumor; Carcinoma, Adenoid Cystic; Carcinoma, Basal Cell; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Mucoepidermoid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Carcinoma, Verrucous; Cholangiocarcinoma; Cholangitis, Sclerosing; CNS Embryonal Tumor; Colonic Neoplasms; Colorectal Neoplasms; Cystadenocarcinoma; Cystadenocarcinoma, Mucinous; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Ependymoma; Esophageal adenocarcinoma; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esthesioneuroblastoma, Olfactory; Fallopian Tube Neoplasms; Gallbladder Neoplasms; Glioblastoma; Glioma; Glioma, Subependymal; Gliosa | Details |
| Gefitinib | ZD-1839 | Approved | Astrazeneca Plc | 易瑞沙, Iressa | Japan | Carcinoma, Non-Small-Cell Lung | Astrazeneca Pharmaceutical Co Ltd | 2002-07-05 | Abdominal Neoplasms; Adenocarcinoma of Lung; Adenocarcinoma, Bronchiolo-Alveolar; Adenocarcinoma, Follicular; Adrenocortical Carcinoma; Astrocytoma; Brain metastases; Brain Neoplasms; Breast Neoplasms; Breast Neoplasms, Male; Carcinoma; Carcinoma, Adenoid Cystic; Carcinoma, Basal Cell; Carcinoma, Basosquamous; Carcinoma, Hepatocellular; Carcinoma, Islet Cell; Carcinoma, Mucoepidermoid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Carcinoma, Verrucous; CNS Embryonal Tumor; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Neoplasms; Esthesioneuroblastoma, Olfactory; Fallopian Tube Neoplasms; Gastrinoma; Gastrointestinal Neoplasms; Glioblastoma; Glioma; Gliosarcoma; Glucagonoma; Granuloma, Lethal Midline; Head and Neck Neoplasms; Hypopharyngeal Neoplasms; Insulinoma; Kidney Neoplasms; Laryngeal Diseases; Laryngeal Neoplasms; Leukemia, Myeloid, Acute; Lip Neoplasms; Liver Neoplasms; Lung Neoplasms; Medullary thyroid cancer (MTC); Mesotheliom | Details |
| Brigatinib | AP-26113 | Approved | Ariad Pharmaceuticals Inc | Alunbrig, ALUNBRIG | United States | Carcinoma, Non-Small-Cell Lung | Takeda Pharmaceuticals USA Inc | 2017-04-28 | Brain metastases; Carcinoma; Carcinoma, Non-Small-Cell Lung; Ependymoma; Granuloma, Plasma Cell; Lung Neoplasms; Lymphoma, Large-Cell, Anaplastic; Meningioma; Myofibroma; Neoplasms; Neurilemmoma; Neurofibromatosis 2; Neuroma, Acoustic; Sarcoma, Kaposi; Solid tumours | Details |
| Recombinant Human Epidermal Growth Factor Derivative (Shenzhen Wastin Genetech) | rEGF | Approved | Shenzhen Watsin Genetech Ltd | 金因肽, GeneTime | Mainland China | Wounds and Injuries | Shenzhen Watsin Genetech Ltd | 2001-01-01 | Wounds and Injuries | Details |
| Nepidermin | DWP-401 | Approved | Daewoong Pharmaceutical Co Ltd | Easyef | South Korea | Alopecia; Diabetic Foot | Daewoong Pharmaceutical Co Ltd | 2001-01-01 | Alopecia; Diabetic Foot; Dry Eye Syndromes | Details |
| Panitumumab N01 | QL-1203; QL1203 | Approved | Qilu Pharmaceutical Co Ltd | 安可泽 | Mainland China | Colorectal Neoplasms | Qilu Pharmaceutical Co Ltd | 2025-12-03 | Colorectal Neoplasms; Solid tumours | Details |
| Icotinib Hydrochloride | BPI-2009H; BPI-2009C | Approved | Betta Pharmaceuticals Co Ltd | 凯美纳, Conmana | Mainland China | Carcinoma, Non-Small-Cell Lung | Betta Pharmaceuticals Co Ltd | 2011-06-07 | Adenocarcinoma; Adenocarcinoma of Lung; Brain metastases; Bronchial Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Esophageal Neoplasms; Lung Neoplasms; Metastatic breast cancer; Nasopharyngeal Carcinoma; Neurofibromatosis 2; Neuroma, Acoustic; Psoriasis; Solid tumours; Stomach Neoplasms | Details |
| Recombinant human EGF conjugated vaccine | Approved | Biotech Pharmaceuticals Co Ltd | Carcinoma, Non-Small-Cell Lung | Details | ||||||
| Recombinant epidermal growth factor (Bharat Biotech) | REGEN-D 60; REGEN-D 150 | Approved | Bharat Biotech International Ltd | India | Diabetic Foot; Burns | Bharat Biotech International Ltd | 2005-01-01 | Burns; Diabetic Foot | Details | |
| Lazertinib Mesylate | YH-25448; JNJ-73841937; JNJ-1937; GNS-1480 | Approved | Janssen Biotech Inc, Oscotec Inc, Yuhan Corp | Leclaza, 利珂, Lazcluze | South Korea | Carcinoma, Non-Small-Cell Lung | Yuhan Corp | 2021-01-18 | Carcinoma, Non-Small-Cell Lung; Hepatic Insufficiency | Details |
| Recombinant epidermal growth factor biosimilar (Elea) | r-hu-EGF | Approved | Elea | Argentina | Diabetic Foot; Burns | Elea | 2015-01-01 | Burns; Diabetic Foot | Details | |
| Recombinant Human Epidermal Growth Factor Derivative Eye Drops (Shenzhen Wastin Genetech) | Approved | Shenzhen Watsin Genetech Ltd | 金因舒, GeneSoft | Mainland China | Corneal Diseases | Shenzhen Watsin Genetech Ltd | 2004-01-21 | Corneal Diseases | Details | |
| Necitumumab | LY-3012211; IMC-11F8 | Approved | Eli Lilly And Company | Portrazza | United States | Carcinoma, Non-Small-Cell Lung | Eli Lilly And Co (Ireland) Ltd | 2015-11-24 | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Neoplasm Metastasis; Neoplasms; Solid tumours | Details |
| Cetuximab N01 | KL-A140; KLA140; A-140; KL-140; KLA-140 | Approved | Sichuan Kelun Pharmaceutical Co Ltd | 达泰莱 | Mainland China | Colorectal Neoplasms | Sichuan Kelun-Biotech Biopharmaceutical Co Ltd | 2025-01-24 | Adenocarcinoma; Cholangiocarcinoma; Colorectal Neoplasms; Neoplasms; Rectal Neoplasms | Details |
| Amivantamab/Hyaluronidase | Approved | Janssen Biotech Inc | Rybrevant Faspro, 锐珂捷 | United States | Carcinoma, Non-Small-Cell Lung | Janssen Biotech Inc | 2025-12-17 | Carcinoma, Non-Small-Cell Lung | Details | |
| Panitumumab | ABX-0303; E7.6.3; ABX-10221; AMG-954; ABX-EGF | Approved | Amgen Inc | Vectibix | United States | Colorectal Neoplasms | Amgen Inc | 2006-09-27 | Adenoma, Pleomorphic; Brain Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Colonic Neoplasms; Colorectal Neoplasms; Esophageal Neoplasms; Exanthema; Gastrointestinal Neoplasms; Glioma; Head and Neck Neoplasms; Kidney Neoplasms; Lung Neoplasms; Malignant Carcinoid Syndrome; Neoplasm Metastasis; Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Rectal Neoplasms; Salivary Gland Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck | Details |
| Neratinib Maleate | HKI-272; PF-0528767; WAY-179272; CAN-030; PB-272 | Approved | Pfizer Inc | Nerlynx, 贺俪安, 汉奈佳, 赫赛佳, Hernera | United States | Breast Neoplasms | Puma Biotechnology Inc | 2017-07-17 | Brain metastases; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Glioblastoma; Hepatic Insufficiency; Lung Neoplasms; Metastatic breast cancer; Neoplasms; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Solid tumours; Stomach Neoplasms; Triple Negative Breast Neoplasms | Details |
| Cetuximab biosimilar (CinnaGen) | Approved | Cinnagen | Iran | Colorectal Neoplasms | Cinnagen | 2017-01-01 | Colorectal Neoplasms | Details | ||
| Lapatinib Ditosylate Hydrate | GW-572016; GW-572016F; GW-2016 | Approved | Glaxosmithkline Plc, Novartis Pharma Ag | Tykerb, Tyverb, 泰立沙, Tykerb/Tyverb | United States | Breast Neoplasms | Novartis Pharma Ag | 2007-03-13 | Abdominal Neoplasms; Adenocarcinoma; Astrocytoma; Bile Duct Neoplasms; Brain metastases; Brain Neoplasms; Breast Neoplasms; Breast Neoplasms, Male; Carcinoma; Carcinoma, Acinar Cell; Carcinoma, Adenoid Cystic; Carcinoma, Hepatocellular; Carcinoma, Mucoepidermoid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Carcinoma, Verrucous; Central Nervous System Neoplasms; CNS Embryonal Tumor; Colorectal Neoplasms; Endometrial Neoplasms; Ependymoma; Esophageal Neoplasms; Gallbladder Neoplasms; Gastroesophageal Junction Neoplasms; Gastrointestinal Neoplasms; Glioblastoma; Glioma; Gliosarcoma; Head and Neck Neoplasms; Hypopharyngeal Neoplasms; Laryngeal Diseases; Laryngeal Neoplasms; Lip Neoplasms; Liver Neoplasms; Lung Neoplasms; Lymphoma; Medulloblastoma; Melanoma; Metastatic breast cancer; Mouth Neoplasms; Nasopharyngeal Carcinoma; Neoplasm Metastasis; Neoplasms; Neoplasms, Gonadal Tissue; Neurofibromatosis 2; Neuroma, Acoustic; Nose Neoplasms; Oligoden | Details |
| Sevabertinib | BAY-2927088 | Approved | Bayer AG, Broad Institute, Harvard University | Hyrnuo | United States | Carcinoma, Non-Small-Cell Lung | Bayer Healthcare Pharmaceuticals Inc, Bayer Healthcare Pharmaceuticals Llc | 2025-11-19 | Carcinoma, Non-Small-Cell Lung; Hepatic Insufficiency; Liver Diseases; Neoplasm Metastasis; Solid tumours | Details |
| Recombinant epidermal growth factor (Shanghai Haohai ) | Approved | Shanghai Haohai Biological Technology Co Ltd | 康合素 | Mainland China | Burns | Shanghai Haohai Biological Technology Co Ltd | 2001-01-01 | Burns | Details | |
| Amivantamab | JNJ-61186372; JNJ-372; JNJ-6372; CNTO4424; CNTO-4424 | Approved | Genmab A/S, Johnson & Johnson Innovative Medicine | RYBREVANT | United States | Carcinoma, Non-Small-Cell Lung | Janssen Biotech Inc | 2021-05-21 | Adenocarcinoma; Carcinoma, Adenoid Cystic; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Neoplasms; Glioblastoma; Glioma; Lung Neoplasms; Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms | Details |
| Recombinant epidermal growth factor drop (Pavay Gene Pharmaceutical) | Approved | Guilin Huanuowei Gene Pharmaceutical Co Ltd | 易贝 | Mainland China | Corneal Diseases | Guilin Huanuowei Gene Pharmaceutical Co Ltd | 2002-04-12 | Corneal Diseases; Xerophthalmia | Details | |
| Pyrotinib Maleate | BLTN; HTI-1001; SHR-1258 | Approved | Jiangsu Hengrui Medicine Co Ltd | 艾瑞妮 | Mainland China | Breast Neoplasms | Jiangsu Hengrui Medicine Co Ltd | 2018-08-12 | Adenocarcinoma of Lung; Bile Duct Neoplasms; Biliary Tract Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Gastroesophageal Junction Neoplasms; Gastrointestinal Neoplasms; Lung Neoplasms; Metastatic breast cancer; Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| Dacomitinib | PF-00299804-03; PF-00299804-3; PF-00299804; PF-299804; PF-299; PF-804 | Approved | Pfizer Inc | Vizimpro | United States | Carcinoma, Non-Small-Cell Lung | Pfizer Inc | 2018-09-27 | Adenocarcinoma; Brain Neoplasms; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Colorectal Neoplasms; Esophageal Squamous Cell Carcinoma; Glioblastoma; Head and Neck Neoplasms; Liver Diseases; Lung Neoplasms; Mouth Neoplasms; Neoplasm Metastasis; Neoplasms; Penile Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms | Details |
| Mouse epidermal growth factor (Hangzhou Tianmushan Pharmaceutical) | Approved | Hangzhou Tianmushan Pharmaceutical Enterprise Co Ltd | 一夫 | Wounds and Injuries | Details |